Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Target Lowered at The Goldman Sachs Group

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective trimmed by The Goldman Sachs Group from $536.00 to $320.00 in a report released on Friday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on ALNY. Jefferies Financial Group increased their target price on shares of Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the stock a “hold” rating in a research report on Tuesday, September 8th. Wells Fargo & Company reduced their price target on shares of Alnylam Pharmaceuticals from $253.00 to $220.00 and set an “equal weight” rating on the stock in a research report on Friday. Needham & Company LLC reduced their price target on shares of Alnylam Pharmaceuticals from $357.00 to $243.00 and set a “buy” rating on the stock in a research report on Thursday. Barclays decreased their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research note on Monday, August 3rd. Finally, UBS Group reissued a “buy” rating and issued a $329.00 price objective (down from $550.00) on shares of Alnylam Pharmaceuticals in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $317.95.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $165.00 on Friday. The business’s fifty day moving average price is $236.49 and its 200 day moving average price is $286.19. Alnylam Pharmaceuticals has a twelve month low of $163.30 and a twelve month high of $479.79. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The stock has a market capitalization of $22.08 billion, a P/E ratio of 8.57 and a beta of 0.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, topping the consensus estimate of $1.66 by $14.60. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 246.94% and a net margin of 52.85%. The firm’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.90 earnings per share. As a group, research analysts anticipate that Alnylam Pharmaceuticals will post 6.43 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the sale, the executive vice president owned 12,807 shares of the company’s stock, valued at $2,905,652.16. This represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Rakuten Investment Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 13.0% during the third quarter. Rakuten Investment Management Inc. now owns 20,289 shares of the biopharmaceutical company’s stock worth $5,155,000 after acquiring an additional 2,328 shares during the last quarter. Provenance Wealth Advisors LLC acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter worth about $527,000. GraniteShares Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals by 12.7% in the third quarter. GraniteShares Advisors LLC now owns 1,825 shares of the biopharmaceutical company’s stock worth $450,000 after acquiring an additional 205 shares in the last quarter. Traynor Capital Management Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 22.6% in the third quarter. Traynor Capital Management Inc. now owns 12,818 shares of the biopharmaceutical company’s stock worth $3,163,000 after acquiring an additional 2,360 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Alnylam Pharmaceuticals in the third quarter valued at about $18,226,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Quarterly results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, slightly above forecasts. The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion–$4.5 billion in 2026 TTR sales. Alnylam Q3 earnings beat
• Positive Sentiment: Several analysts still see substantial long-term upside. Chardan Capital, TD Cowen, Goldman Sachs and RBC retained positive ratings, although they reduced their price targets. Their revised targets remain well above the current trading level. Chardan Capital rating
• Neutral Sentiment: Pipeline investment could support future growth but increases execution risk. Alnylam expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an anticipated launch around 2030. Management described its conviction in the program as high, but the longer timeline limits near-term revenue benefits. Alnylam TTR sales and trial update
• Negative Sentiment: Demand-growth concerns overshadowed the earnings beat. Slower Amvuttra patient starts and moderating U.S. Amvuttra and Onpattro sales growth raised concerns that the company’s core TTR business may be losing momentum. Management also acknowledged that it needs to improve execution, adding to uncertainty around the franchise. ALNY demand growth concerns
• Negative Sentiment: Analyst sentiment became more cautious. Bernstein downgraded ALNY to “market perform,” while Stifel cut its rating to “hold.” Multiple firms lowered price targets, including Bernstein from $376 to $199 and Goldman Sachs from $536 to $320, reflecting increased valuation and policy risks.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.